Bora CDMO Bora CDMO

X

Find Palonosetron manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES

0

Palonosetron
Also known as: 135729-62-3, Palonosetron hcl, Aloxi, Onicit, Palonosetron (hydrochloride), Rs-25259-197
Molecular Formula
C19H25ClN2O
Molecular Weight
332.9  g/mol
InChI Key
OLDRWYVIKMSFFB-SSPJITILSA-N
FDA UNII
23310D4I19

Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.
1 2D Structure

Palonosetron

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one;hydrochloride
2.1.2 InChI
InChI=1S/C19H24N2O.ClH/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20;/h2,4,6,13,15,17H,1,3,5,7-12H2;1H/t15-,17-;/m1./s1
2.1.3 InChI Key
OLDRWYVIKMSFFB-SSPJITILSA-N
2.1.4 Canonical SMILES
C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5.Cl
2.1.5 Isomeric SMILES
C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5.Cl
2.2 Other Identifiers
2.2.1 UNII
23310D4I19
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz(de)isoquinolin-1-one

2. 2-qhbiqo

3. Aloxi

4. Palonosetron

5. Palonosetron, (3r)-

6. Palonosetron, (r-(r*,r*))-isomer

7. Palonosetron, (r-(r*,s*))-isomer

8. Palonosetron, (s-(r*,s*))-isomer

9. Rs 25233 197

10. Rs 25233 198

11. Rs 25233-197

12. Rs 25233-198

13. Rs 25233197

14. Rs 25233198

15. Rs 25259

16. Rs 25259 197

17. Rs 25259 198

18. Rs 25259-197

19. Rs 25259-198

20. Rs 25259197

21. Rs 25259198

22. Rs-25233-197

23. Rs-25233-198

24. Rs-25259

25. Rs-25259-197

26. Rs-25259-198

27. Rs25233197

28. Rs25233198

29. Rs25259

30. Rs25259197

31. Rs25259198

2.3.2 Depositor-Supplied Synonyms

1. 135729-62-3

2. Palonosetron Hcl

3. Aloxi

4. Onicit

5. Palonosetron (hydrochloride)

6. Rs-25259-197

7. (s,s)-palonosetron Hydrochloride

8. Palonocetron Hydrochloride

9. Palonosetron (as Hydrochloride)

10. Chebi:85157

11. Rs 25259-197

12. (3as)-2-(3s)-1-azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1h-benz[de]isoquinolin-1-one Monohydrochloride

13. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one;hydrochloride

14. 1h-benz[de]isoquinolin-1-one, 2-[(3s)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-, Hydrochloride (1:1), (3as)-

15. 23310d4i19

16. Aloxi (tn)

17. Dsstox_cid_26610

18. Dsstox_rid_81765

19. Dsstox_gsid_46610

20. (3as)-2,3,3a,4,5,6-hexahydro-2-((3s)-3-quinuclidinyl)-1h-benz(de)isoquinolin-1-one Monohydrochloride

21. (s)-2-((s)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benzo[de]isoquinolin-1-one Hydrochloride

22. (r,s)-palonosetron Hcl

23. (s,r)-palonosetron Hcl

24. Cas-135729-62-3

25. Palonosetron Related Compound C

26. Palonosetron Related Compound D

27. Onicita

28. Paloxi

29. Palonosetron Hydrochloride [usan]

30. Unii-23310d4i19

31. Palonosetron Hydrochloride [usan:jan]

32. Palonosetronhydrochloride

33. Ncgc00166415-01

34. Chembl1720

35. Mls001424202

36. Schembl182478

37. Rs 25259 197

38. Dtxsid8046610

39. (3as)-palonosetron Hydrochloride

40. Palonosetron Hydrochloride- Bio-x

41. Palonosetron Hydrochloride (aloxi)

42. Ex-a4360

43. Hy-a0021

44. Tox21_112421

45. Mfcd00939524

46. Nsc743769

47. S3050

48. Palonosetron Hydrochloride (jan/usp)

49. Akos015895112

50. Akos026751493

51. Tox21_112421_1

52. Ac-1293

53. Ccg-101081

54. Ccg-221268

55. Cs-0621

56. Nc00331

57. Palonosetron Hydrochloride [mi]

58. Palonosetron Hydrochloride [jan]

59. Ncgc00166415-03

60. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one Hydrochloride

61. As-75066

62. Bp164227

63. Palonosetron Hydrochloride [mart.]

64. Rs 25259

65. Smr000469233

66. Palonosetron Hydrochloride [usp-rs]

67. Palonosetron Hydrochloride [who-dd]

68. Palonosetron Hydrochloride, >=98% (hplc)

69. P-225

70. P2051

71. Palonosetron Hydrochloride [ema Epar]

72. D05343

73. Palonosetron Hydrochloride [orange Book]

74. 729p623

75. Akynzeo Component Palonosetron Hydrochloride

76. Palonosetron Hydrochloride [usp Monograph]

77. 7-amino-3-(hydroxymethyl)-3-cephem-4-carboxylicacid

78. Palonosetron Hydrochloride Component Of Akynzeo

79. Q27158366

80. (s,r)-palonosetron Hydrochloride Contains Up To ~35% (r,r)-isomer

81. 1h-benz[de]isoquinolin-1-one,3,3a,4,5,6-hexahydro-, (3as)- Hydrochloride

82. 1h-benz[de]isoquinolin-1-one,3,3a,4,5,6-hexahydro-, [s-(r*,r*)]-, Hydrochloride

83. Palonosetron Hydrochloride, United States Pharmacopeia (usp) Reference Standard

84. (3as)-2-[(3s)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1h-benz[de]isoquinolin-1-one Hydrochloride

85. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1h-benzo[de]isoquinolin-1-one--hydrogen Chloride (1/1)

86. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one;hydrochloride.

87. (3as)-2-[(s)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1h-benz[de]isoquinoline Hydrochloride

88. (3s)-3-[(3as)-1-oxo-3a,4,5,6-tetrahydro-1h-benzo[de]isoquinolin-2(3h)-yl]-1-azabicyclo[2.2.2]octan-1-ium Chloride

89. (5s)-3-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-azatricyclo[7.3.1.0?,(1)(3)]trideca-1(13),9,11-trien-2-one Hydrochloride

90. 1h-benz(de)isoquinolin-1-one, 2-(3s)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, Monohydrochloride, (3as)-

2.4 Create Date
2006-07-28
3 Chemical and Physical Properties
Molecular Weight 332.9 g/mol
Molecular Formula C19H25ClN2O
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count2
Rotatable Bond Count1
Exact Mass332.1655411 g/mol
Monoisotopic Mass332.1655411 g/mol
Topological Polar Surface Area23.6 Ų
Heavy Atom Count23
Formal Charge0
Complexity456
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NamePalonosetron hydrochloride
Drug LabelALOXI (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3aS)-2-[(S)-1-Azabicyclo [2.2.2]...
Active IngredientPalonosetron hydrochloride
Dosage FormInjectable
Routeinjection
Strength0.25mg/0.25ml; 0.25mg/5ml; 0.05mg/ml; 0.075mg/1.5ml
Market StatusTentative Approval
CompanyTeva Pharms; Dr Reddys Labs

2 of 2  
Drug NamePalonosetron hydrochloride
Drug LabelALOXI (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3aS)-2-[(S)-1-Azabicyclo [2.2.2]...
Active IngredientPalonosetron hydrochloride
Dosage FormInjectable
Routeinjection
Strength0.25mg/0.25ml; 0.25mg/5ml; 0.05mg/ml; 0.075mg/1.5ml
Market StatusTentative Approval
CompanyTeva Pharms; Dr Reddys Labs

4.2 Drug Indication

Aloxi is indicated in adults for:

- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,

- the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Aloxi is indicated in paediatric patients 1 month of age and older for:

- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antiemetics

Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)


Serotonin 5-HT3 Receptor Antagonists

Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS. (See all compounds classified as Serotonin 5-HT3 Receptor Antagonists.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Serotonin-3 Receptor Antagonist [EPC]; Serotonin 3 Receptor Antagonists [MoA]
5.3 ATC Code

A04AA05


left grey arrow
right gray arrow
  • CAPSULE;ORAL - 300MG;EQ 0.5MG BASE
  • SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)
  • POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL
  • SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)
  • INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY